T04.01.24 MAYO ENDOSCOPIC SCORE AND ULCERATIVE COLITIS ENDOSCOPIC INDEX ARE EQUALLY EFFECTIVE FOR ENDOSCOPIC ACTIVITY EVALUATION IN ULCERATIVE COLITIS PATIENTS AMONG HOSPITAL ENDOSCOPISTS IN A SINGLE CENTER

2020 ◽  
Vol 52 ◽  
pp. S127
Author(s):  
C. Pagnini ◽  
M.C. Di Paolo ◽  
R. Urgesi ◽  
L. Pallotta ◽  
A.M. Vitale ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Single Center ◽  
Activity Evaluation ◽  
Endoscopic Score

scholarly journals Mayo Endoscopic Score and Ulcerative Colitis Endoscopic Index Are Equally Effective for Endoscopic Activity Evaluation in Ulcerative Colitis Patients in a Real Life Setting

2021 ◽  
Vol 12 (2) ◽  
pp. 217-224
Author(s):  
Cristiano Pagnini ◽  
Maria Carla Di Paolo ◽  
Benedetta Maria Mariani ◽  
Riccardo Urgesi ◽  
Lorella Pallotta ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Real Life ◽  
Observer Agreement ◽  
Activity Evaluation ◽  
Video Recordings ◽  
Real Life Setting ◽  
Bowel Diseases ◽  
Endoscopic Score ◽  
And Performance ◽  
Similar Good

The role of endoscopic evaluation in ulcerative colitis (UC) is well recognized, but a universally accepted gold standard for endoscopic activity evaluation is still lacking, and many scores have been proposed to this purpose. Among these, the Mayo Endoscopic Score (MES) and the Ulcerative Colitis Endoscopic Index (UCEIS) are currently the most used in trials and clinical practice. The aim of the study is to evaluate feasibility and performance of MES and UCEIS among expert endoscopists with no specific expertise in inflammatory bowel diseases (IBD), in a single hospital center. Two minutes video recordings, from colonoscopy of 12 UC patients, were observed and scored, according to MES and UCEIS, by seven hospital gastroenterologists with experience in digestive endoscopy and no particular expertise in IBD. Knowledge and utilization of the two scores were investigated. Inter-observer agreement and agreement with an IBD-expert gastroenterologist of the same center (central reader), and correlation between the two scores, was calculated. Among the endoscopists, MES was much more known and currently used than UCEIS. Both the scores displayed a similar good performance. Agreement with central reader was moderate for MES and UCEIS, and interobserver agreement was good, for both MES and UCEIS. Correlation between the two scores was very good both for central reader and for the hospital endoscopists. This single center study confirmed potential feasibility and usefulness of MES and UCEIS for assessment of endoscopic activity in UC patients in a real-life setting.

scholarly journals Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?

2021 ◽  
Vol 10 (23) ◽  
pp. 5551
Author(s):  
Panu Wetwittayakhlang ◽  
Livia Lontai ◽  
Lorant Gonczi ◽  
Petra A. Golovics ◽  
Gustavo Drügg Hahn ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Current Evidence ◽  
Treat To Target ◽  
Therapeutic Goal ◽  
Treatment Targets ◽  
Patient Reported ◽  
Clinical Biomarker ◽  
Endoscopic Score ◽  
Histological Remission

The main therapeutic goal of ulcerative colitis (UC) is to induce and maintain remission to prevent long-term disease progression. Treat-to-target strategies, first introduced by the STRIDE consensus and updated in 2021, have shifted focus from symptomatic control toward more stringent objective endpoints. Today, patient monitoring should be based on a combination of biomarkers and clinical scores, while patient-reported outcomes could be used as short-term targets in monitoring disease activity and therapeutic response. In addition, endoscopic healing was the preferred long-term goal in UC. A Mayo endoscopic score (MES) ≤ 1 can be recommended as a minimum target. However, recent evidence suggests that more stringent endoscopic goals (MES of 0) are associated with superior outcomes. Recently, emerging data support that histological remission (HR) is a superior prognostic factor to endoscopic healing in predicting long-term remission. Despite not yet being recommended as a target, HR may become an important potential therapeutic goal in UC. However, it remains questionable if histological healing should be used as a routine assessment in addition to clinical, biomarker, and endoscopic targets in all patients. Therefore, in this review, our aim was to discuss the current evidence for the different treatment targets and their value in everyday clinical practice.

Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single center

2015 ◽  
Vol 15 (9) ◽  
pp. 1257-1262 ◽  
Author(s):  
Klaudia Farkas ◽  
Mariann Rutka ◽  
Anita Bálint ◽  
Ferenc Nagy ◽  
Renáta Bor ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Induction Therapy ◽  
Single Center

scholarly journals P276 Reactivation of Epstein–Barr virus and cytomegalovirus behaves differently in pathophysiology of ulcerative colitis

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S289-S289
Author(s):  
S Yamada ◽  
S Yamamoto ◽  
Y Honzawa ◽  
Y Hayashi ◽  
H Kitamoto ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Multivariate Analysis ◽  
Epstein Barr Virus ◽  
Colonic Mucosa ◽  
Clinical Severity ◽  
Barr Virus ◽  
Ebv Reactivation ◽  
Endoscopic Score ◽  
Epstein Barr ◽  
Cmv Reactivation

Abstract Background Cytomegalovirus (CMV) and Epstein–Barr virus (EBV) are members of the herpesvirus family. CMV reactivation is often complicated with ulcerative colitis (UC) and is known as one of exacerbation factors. However, the association between EBV reactivation and pathophysiology of UC is still unclear. Methods This study enrolled 116 active UC patients who received colonoscopy between January 2005 and January 2019 in Kyoto University Hospital. 244 biopsy specimens were obtained from inflamed colonic mucosa to assess EVB and CMV reactivation. Viral loads of EBV and CMV in inflamed mucosa were measured by real-time PCR assay. The reactivation of those viruses was defined as DNA quantity more than 10 copies/μg DNA. Clinical severity was assessed by Lichtiger index and defined as follow: 4–8 as mild, 9–12 as moderate, and more than 12 as severe. Endoscopic severity was assessed by Mayo endoscopic score. We examined the correlation between the positivity of each viral reactivation and patients’ characteristics or prognosis of UC. Results (1) Median age, Lichtiger score and Mayo endoscopic score at the time to assess the viral reactivations were 36 years-old, 8, and 3, respectively. (2) EBV and CMV reactivation were observed in 127 samples (52.0%) and 73 samples (29.9%), respectively. There was no correlation between EBV and CMV viral load (correlation coefficient 0.19), although a significant correlation between those viral reactivations was observed in active colonic mucosa of UC patients (p = 0.002). (3) The proportion of EBV reactivation was higher in both clinically and endoscopically severe UC patients compared with those with mild activity. On the other hands, there was no association between CMV reactivation and clinical or endoscopic severity. (4) Multivariate analysis indicated risk factors for EBV reactivation as receiving anti-TNF-α antibodies (odds ratio [OR] 4.2) or calcineurin inhibitors (OR 3.5), and CMV reactivation (OR 2.1), respectively. (5) Multivariate analysis also indicated risks for CMV reactivation as steroid-refractory (OR 4.7) and EBV reactivation (OR 2.0). (6) EBV and CMV reactivation did not affect clinical outcomes including the requirement of colectomy or intensification of immunosuppressive treatments and the incidence of colitis-associated cancer, dysplasia and lymphoproliferative disease. Conclusion Reactivation of EBV or CMV may behave differently in pathophysiology of UC. Further studies are required to clarify the role of EBV reactivation on colonic inflammation in UC patients.

scholarly journals Relationship between Mayo endoscopic score and histological scores in ulcerative colitis: A prospective study

JGH Open ◽  
2019 ◽  
Vol 4 (3) ◽  
pp. 382-386
Author(s):  
Jimil Shah ◽  
Usha Dutta ◽  
Ashim Das ◽  
Vishal Sharma ◽  
Harshal Mandavdhare ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Prospective Study ◽  
Endoscopic Score ◽  
A Prospective Study

Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohnʼs disease: A single-center experience

2008 ◽  
Vol 14 (1) ◽  
pp. 7-12 ◽  
Author(s):  
Aaron Benson ◽  
Terrence Barrett ◽  
Marshall Sparberg ◽  
Alan L. Buchman
Keyword(s):  
Ulcerative Colitis ◽  
Efficacy And Safety ◽  
Single Center ◽  
Single Center Experience
Sign in / Sign up

Export Citation Format

Share Document